EPS and sales below estimates but raised its 2025 revenue outlook, driven by CF drug demand and new product launches in the U ...

Vertex has recorded some 25,000 prescriptions for Journavx since its January approval and is in the process of getting big ...

For Vertex Pharmaceuticals, the first quarter of 2025 brought good news and bad news. | Despite positive early signs for its ...

The cell and gene therapy space in recent months has hit several speedbumps, including layoffs, dropped drugs and ...

Vertex also picked up a positive Committee for Medicinal Products for Human Use (CHMP) opinion for Alyftrek. As a result, it's looking for European Commission approval for the drug in the second half ...

Vertex shares fell in after-hours trading, as investors considered a stock trading near its all-time high with a longer wait ...

Vertex said its profit fell due to higher operating expenses and a $379 million intangible asset impairment charge associated with treatment for Type 1 diabetes patients, which the company said in ...

Vertex, Inc. (VERX) kicks off 2025 strong with 12.9% revenue growth, strategic AI investments, and e-invoicing innovations.

Good day, and welcome to the Vertex Pharmaceuticals First Quarter 2025 Earnings Call. [Operator Instructions]. Please note this event is being recorded. I would now like to turn the conference ...

Google Cloud’s latest enhancements to Vertex AI and the Gemini model family offer businesses a comprehensive solution for building, deploying, and managing AI applications with unprecedented ...

A decade has passed since a short-lived railcar manufacturer opened its doors in Wilmington. At an invitation-only event in November 2014, many promises were made on behalf of Vertex Rail Technologies ...